Resverlogix Corporation Announces Milestone ApoA-l/HDL Proof-of-Concept Data

CALGARY, ALBERTA -- (MARKET WIRE) -- April 25, 2007 -- Resverlogix Corp. ("Resverlogix") (TSX: RVX) announced today that the Company has released pivotal proof-of-concept data in non-human primates for the NexVas PR program. Interim results from a long term study in adult African Green monkeys demonstrate that oral administration once daily of RVX-208 for 28 days increased the levels of serum ApoA-I and HDL-cholesterol. Serum ApoA-l increased by 52% and high-density lipoprotein (HDL) cholesterol increased by 95% with RVX-208 treatment. Data collected at Day 42 demonstrated a sustained treatment effect. This data coupled with the recently announced toxicology data represents a significant achievement and further highlights the value of the Company's proprietary small molecule platform.